Early screening

We harvest the potential of two fundamental indicators of cancer:
tumor metabolism and extracellular vesicles

Learn More


We provide high quality services to support fundamental and streamlined EV research
Learn More


Meet the Exosomics Team

Learn more

our Mission

Our mission is to develop and commercialize a new generation of tests for cancer screening and liquid biopsy, based on analysis of circulating extracellular vesicles and exosomes.

our vision

<style=”text-align: justify;”>A world in which a simple blood draw will be sufficient for early cancer diagnosis, enabling physicians to select the best course of treatment, ultimately resulting in better patient outcomes.

our values

Caring with Honesty – High Standards – Making a Difference Through Innovative Thinking – Teamwork – Partnership and Trust

Exosomics’ strengths


We provide accurate tumor biopsy from a routine blood draw, truly suitable for low interval screening and for active surveillance and monitoring.


We rely on a unique biological principle and evolving science to build and validate highly sensitive and specific diagnostic tests.



Our approach is based on the detection of fundamental drivers of cancer (e.g. metabolic switch) and exosomes as early sentinels of tumor occurrence.


Our tests are simple, reliable, and cost-effective; we offer scalable and familiar test formats and provide them as open platform solutions.


Current investors are: Lonza, BioBalt Holding, BioFund, FinBiotech Srl, and Black Swan Trade Ltd.